News on clinical chemistry systems and applications.
The test leverages a novel cancer biomarker that may improve the accuracy and sensitivity of noninvasive bladder cancer testing.
The company will donate full laboratory set-ups to the effort and provide training and education to implement screening programs.
Along with predicting preeclampsia, the Delfia Xpress sFlt-1 kit can be used to help diagnose the condition in the second and third trimesters of pregnancy.
While Sera's previous validation work focused on the 37 and 35 week time points, the 32 week mark is perhaps most crucial in terms of patient outcomes.
The assays quantitatively measure the activity of galactose-1-phosphate uridylyltransferase and biotinidase enzymes from newborn dried blood spot specimens.
